Supercharging Microglia for Brain Health
Owl Therapeutics
Supercharged Microglial Pipeline: What makes us different?
Our supercharged microglial drug pipeline for Alzheimer's disease (AD), traumatic brain injury (TBI), and adjacent brain indications is powered by key generative AI and biomarker technologies .
Supercharged Microglial Drug Pipeline
-
OWL-1023-AI (late preclinical): A best-in-class monoclonal antibody engineered to enhance microglial
phagocytosis (eating) of
brain cell debris. -
OWL-4130-AI (late preclinical): A best-in-class fusion protein engineered to enhance microglial clearance of inflammation.
-
OWL-1410 (clinical) and OWL-1410-AI (early preclinical): A first-in-class and best-in-class small molecule engineered to enhance protection of mitochondrial “powerhouses” in microglia and other brain cells.
Generative AI Power
We develop and apply novel generative AI tools to engineer large and small molecule drugs that supercharge microglia-with predicted improvements in efficacy and safety. We verify our predictions with high throughput experiments for microglial clearance, inflammation, and mitochondrial function.
Biomarker Power
Through a partnership with Gryphon Bio, we reverse-translate blood biomarkers from clinical studies to improve the odds of successful preclinical studies, as well as future clinical trials, with our microglial drugs.